Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2017

View Archived Issues

Boehringer Ingelheim and MiNa Therapeutics to collaborate on compounds for fibrotic liver diseases

CellSight, Boehringer Ingelheim to evaluate use of VisAcT in monitoring immune-oncological therapies

AVERTS-2 phase III trial of Otividex meets primary efficacy endpoint

ImmunoMolecular Therapeutics as new spinout of Barbara Davis Center for Diabetes

FDA grants QIDP status to BIOC-51

Protagonist Therapeutics begins phase I study of PTG-200

FDA accepts Otsuka's resubmitted NDA for tolvaptan

Phase I study of BRAF inhibitor PLX-8394 identifies dose for phase II

FDA approves Adcetris in new indication

NICE recommends Mavenclad in final appraisal determination

Sage's phase III trials of brexanolone in postpartum depression meet primary endpoints

Principia to grant Sanofi worldwide license to develop and commercialize PRN-2246

Inotrem collaborates with Roche Diagnostics on septic shock companion diagnostic

FDA approves Heplisav-B for prevention of hepatitis B in adults

FDA approves Cinvanti for prevention of acute and delayed chemotherapy-induced nausea and vomiting

Lundbeck reports highlights of third quarter 2017

Alnylam reaches alignment with FDA on safety measures for fitusiran program

vTv Therapeutics initiates simplici-T1 study of TTP-399 in type 1 diabetes

New phase I trial studies polio vaccine JNJ-64152348 in healthy adults

Zosano initiates long-term safety study of M-207 for migraine

Merck KGaA describes novel PDH kinase 2 inhibitors

Duke University discovers bacterial LpxC inhibitors

Novel retinoid RORgammaT receptor modulators identified at Janssen

Yuhan patents new PI3Kdelta inhibitors

Guangzhou Henovcom Bioscience discloses novel influenza virus neuraminidase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...